$2.5 B

XLRN Mkt cap, 18-Sep-2018

$6.9 M

Acceleron Pharma Revenue Q2, 2018
Acceleron Pharma Net income (Q2, 2018)-55.2 M
Acceleron Pharma EBIT (Q2, 2018)-57.5 M
Acceleron Pharma Cash, 30-Jun-201879.6 M

Acceleron Pharma Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

57.2 m14.6 m18.1 m27.8 m13.5 m

Revenue growth, %

(74%)24%53%

R&D expense

68.6 m89.7 m

General and administrative expense

25.3 m33.7 m

Operating expense total

93.9 m123.5 m

EBIT

7 m(55.5 m)(60.9 m)(66.1 m)(110 m)

EBIT margin, %

12%(379%)(336%)(238%)(816%)

Interest expense

2.1 m922 k

Interest income

39 k83 k512 k1.9 m2.6 m

Pre tax profit

(21.9 m)(51.3 m)(63.9 m)(57 m)(108.4 m)

Income tax expense

(24 k)(32 k)

Net Income

(21.9 m)(51.3 m)(63.9 m)(57 m)(108.5 m)

Quarterly

USDQ1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

3.3 m5.7 m4.2 m18.2 m3.2 m3 m3.7 m3.1 b3.2 m6.9 m

R&D expense

11.8 m14.2 m13.3 m16.2 m16.1 m17.1 m21.7 m21.6 b23.4 m49.4 m

General and administrative expense

3.8 m4.7 m5.4 m5.9 m6.7 m6.4 m7.8 m11.4 b7.4 m15.1 m

Operating expense total

15.5 m18.8 m18.8 m22.2 m22.9 m23.5 m29.6 m33 b30.9 m64.5 m

EBIT

(12.2 m)(13.1 m)(14.6 m)(4 m)(19.7 m)(20.5 m)(25.9 m)(29.9 b)(27.6 m)(57.5 m)

EBIT margin, %

(369%)(229%)(352%)(22%)(615%)(682%)(698%)(978%)(855%)(832%)

Interest expense

922 k

Interest income

13 k154 k139 k334 k503 k512 k502 k476 m1.3 m2.7 m

Pre tax profit

(20.8 m)(25.4 m)(29.7 b)(26.2 m)(55.1 m)

Income tax expense

20 k(6 k)(6 m)(10 k)(21 k)

Net Income

(9.1 m)(10.4 m)(11.9 m)5.1 m(22 m)(25.4 m)(29.7 b)(26.2 m)(55.2 m)

Acceleron Pharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

113.2 m176.5 m27.8 m21 m100.2 m

Accounts Receivable

11.5 m

Inventories

2.2 m2.5 m2.5 m3.9 m

Current Assets

119 m182.3 m110.9 m146.8 m285.2 m

PP&E

3.7 m3.1 m3.1 m5.2 m7 m

Total Assets

123.7 m186.3 m146.3 m247.6 m389.2 m

Accounts Payable

885 k724 k875 k1.6 m1.1 m

Current Liabilities

27.2 m9.3 m14.5 m16.1 m16.7 m

Total Liabilities

22.1 m24 m

Additional Paid-in Capital

250.1 m399.8 m416.9 m590.5 m839.1 m

Retained Earnings

(192.3 m)(243.6 m)(307.5 m)(364.5 m)(473 m)

Total Equity

57.8 m156.3 m109.3 m225.6 m365.2 m

Financial Leverage

2.1 x1.2 x1.3 x1.1 x1.1 x

Quarterly

USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

214.1 m43.4 m63.7 m37 m31 m33.2 m30.7 m69.7 m79.6 m

Current Assets

218.5 m122.4 m170.7 m127 m145 m149 m148.4 m300.3 m299.1 m

PP&E

3.7 m2.9 m3.7 m4.2 m4.2 m7.1 m7.2 m7 m6.9 m

Total Assets

223 m158.4 m289.6 m274.2 m262.9 m229.1 m208.5 m370 m351.5 m

Accounts Payable

2.3 m2.6 m1.2 m566 k2.1 m911 k1.7 m1.7 m1.3 m

Current Liabilities

9.2 m12.9 m15.2 m13.7 m16.2 m15.2 m14.3 m12.9 m14.6 m

Total Liabilities

42.6 m26.6 m29.3 m30.4 m33.3 m20.8 m19.9 m16.3 m18.4 m

Additional Paid-in Capital

381.9 m412.2 m562.6 m568 m574.8 m598.7 m608.5 m850.6 m858.6 m

Retained Earnings

(201.4 m)(280.4 m)(302.4 m)(324.4 m)(345.2 m)(390 m)(419.6 m)(495.5 m)(524.5 m)

Total Equity

180.5 m131.8 m260.3 m243.9 m229.5 m208.3 m188.5 m353.8 m333.1 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x1.1 x1.1 x1.1 x1 x1.1 x

Acceleron Pharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.9 m)(51.3 m)(63.9 m)(57 m)(108.5 m)

Depreciation and Amortization

915 k1.1 m1.2 m1.7 m2.8 m

Inventories

(823 k)(255 k)7 k(1.4 m)

Accounts Payable

(53 k)(161 k)151 k644 k(504 k)

Cash From Operating Activities

(19.7 m)(53.2 m)(44.2 m)(44.7 m)(76.7 m)

Purchases of PP&E

(307 k)(514 k)(959 k)(3.4 m)(4.4 m)

Cash From Investing Activities

(307 k)(514 k)(109 m)(108.8 m)(64.4 m)

Long-term Borrowings

(3.7 m)(16.3 m)

Cash From Financing Activities

93.5 m117 m4.5 m146.7 m220.3 m

Interest Paid

1.7 m1.6 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(9.1 m)(10.4 m)(11.9 m)5.1 m(22 m)(25.4 m)(26.2 m)(55.2 m)

Depreciation and Amortization

904 k1.9 m

Accounts Payable

891 k2.6 m3.3 m1.6 m1.8 m2.6 m1.2 m566 k2.1 m911 k591 k183 k

Cash From Operating Activities

(23.4 m)(45.6 m)

Purchases of PP&E

(504 k)(1.4 m)

Cash From Investing Activities

(11.9 m)18.1 m

Cash From Financing Activities

4.9 m7 m

Acceleron Pharma Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Phase III Trials Products

2 2
Report incorrect company information